Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

Pharmacy Benefit Update Fall/Winter 2021 Issue

PDL Changes: This issue of the Pharmacy Benefit Updates contains information about changes to the Preferred Drug List for January 1, 2022, as well as updates on MaineCare pharmacy benefit changes.

Preferred

ACTEMRA	ADVAIR DISKUS	ANORO ELLIPTA	AVSOLA
BEPREVE	BYSTOLIC	CABENUVA	CLENPIQ SOL
CLONIDINE ER	COLCHICINE TAB	COPAXONE 40MG	CORTISPORIN-TC SUSP
DETROL LA CAP	DEXTROAMPHETAMINE SULFATE TAB	DIASTAT	DIBUCAINE OINT
DUPIXENT	ELIDEL CREA	EFAVIRENZ-EMTRICITABINE-TENOFOVIR DF TAB	EPIDIOLEX
EQUETRO	ESPEROCT	FML DROPS SUSP 1%	GABITRIL TABS
HEMLIBRA	HUMULIN 70/30 KWIKPEN	HUMULIN70-30 VIAL	IMITREX NASAL SPRAY
INCRUSE ELLIPTA	KOGENATE FS	LAMICTAL ODT	LAMICTAL XR
LASTACAFT	LIDOCAINE CREAM	LIDOCAINE PATCH 4%	LINZESS 145mcg
LINZESS 290mcg	MEPERIDINE SOL	METHYLPHENIDATE CD CAP	METHYLPHENIDATE ER TAB
METHYLPHENIDATE ER TABS 24	METHYLPHENIDATE LA CAP	METOPROLOL-HYDROCHLOROTHIAZIDE TAB	MVASI
MYRBETRIQ	NUCYNTA ER	OFEV	OLANZAPINE ODT
ONDANSETRON ODT	ONDANSETRON TAB	ONTRUZANT	ORIAHNN
OTEZLA	PRED FORTE SUSP 1%	PREGABALIN CAPS	QUDEXY XR
QUETIAPINE XR	RECOMBINATE SOLR	REPATHA	RITALIN LA
RITUXAN	SAPHRIS	SIMPONI PEN	SOLIFENACIN SUCCINATE TAB
TECFIDERA	TERCONAZOLE CREAM	TOPAMAX SPRINKLE IR CAPS	TOUJEO
TRAZIMERA	XIGDUO XR TAB	ZADITOR SOLN	ZIRABEV
ZOLMITRITAN SPRAY			

Non-Preferred

NUWIQ	MEPERIDINE TABS	BUTALBITAL COMPOUND-CODEINE CAP	LEVORPHANOL TARTRATE TAB
MORPHINE SULFATE ER TB12	OXYCODONE ORAL CONC	PENTAZOCINE/NALOXONE TABS	GABAPENTIN SOL
LEVETIRACETAM ER TABS	PREGABALIN (ORAL) SOL	TOPIRAMATE ER CAPS	HUMALOG KWIKPEN U-200
AVASTIN VIAL	FANAPT	FLUPHENAZINE HCL CONC	TRUVADA TAB
TAMIFLU TAB	TAMIFLU SUS	RIMANTADINE TAB	INDERAL XL CAP
INNOPRAN XL	ZTLIDO	TRIMETHOBENZAMIDE CAP	MITIGARE
GRANIX VIAL	SUMATRIPTAN NASAL SPRAY	ZOLMITRIPTAN ODT	DIMETHYL FUMARATE CAP
PRED-G S.O.P. OINT	FLUOROMETHOLONE SUSP	LOTEMAX SM DROPS GEL 0.38 %	CINQAIR
ASMANEX	BEVESPI AEROSPHERE		

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

Criteria

Breo Ellipta is moving to non-preferred with a grace period for current user through 3/31/22.
Spiriva Respimat is moving to non-preferred with a grace period for current user through 3/31/22.
Vyvanse chew moving to non-preferred with a grace period for current user through June 2022.
Myfembree and Oriahnn are preferred but require double step through and NSAID and an oral contraceptive.
Dupixent will be preferred but require a clinical PA limited to patient with asthma not controlled on high dose ICS-LABA who have eosinophil greater than or equal to 150 cells or the patient is depend on an oral corticosteroid
Linzess 72mcg will be non-preferred all current users will be grandfathered.

Effective 10/15/2021, pharmacies may submit claims for administration of a booster dose of the Pfizer-BioNTech COVID-19 vaccine for dates of service on or after September 10, 2021. A booster dose is a single dose of the vaccine that may be administered to individuals as defined in the CDC guidance.

The Submission Clarification Code **(420-DK)** field should be used to differentiate which dose is being administered to allow proper reimbursement.

Submission Clarification Code = 10 should be used for the booster dose for population with waning immunity. This guidance applies regardless if the same provider or different providers administered the initial 2-dose series.

Submission Clarification Code = 7 should be used for the additional dose for immunocompromised patients

In general, claims submitted for zero-cost vaccines should be submitted on a single B1/B3 billing transaction including the following data elements and values. Please refer to the **NCPDP EMERGENCY PREPAREDNESS GUIDANCE V1.11** document on the NCPDP.org website for additional information.

The of Office of MaineCare Services (OMS) would like to inform Pharmacy providers that **Effective 12/10/2021**, MaineCare will expand access to Food and Drug Administration (FDA) approved and FDA Emergency Use Authorized (EUA) over the counter (OTC), direct to consumer (DTC), and prescription COVID-19 at-home tests and the OTC, DTC, and prescription COVID-19 home collection kits through a Standing Order for MaineCare beneficiaries. This Standing Order authorizes licensed pharmacists to create a prescription for the OTC, DTC, or prescription COVID-19 at home tests and the OTC, DTC, or prescription COVID-19 home collection kits for eligible MaineCare members.

The following products will be preferred on the MaineCare PDL.

Product Name	NDC
INTELISWAB KIT COVID-19	08337000158

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

LUCIRA KIT COVID-19	10055097000
BINAXNOW COV KIT HOME TES	11877001133
QUICKVUE HOM KIT COVID-19	14613033968
QUICKVUE HOM KIT COVID-19	14613033972
ELLUME COV19 KIT HOME TES	56964000000
BINAXNOW COV KIT HOME TES	11877001140

Office of MaineCare Services are implemented changes to Buprenorphine criteria at the point of sale (POS) effective 7/1/21 for detailed information please see the Prior Authorization Process for Buprenorphine Frequently Asked Questions link listed below: Buprenorphine FAQ July 2021

Top Five Drugs by PA	
DRUG	**CLAIM COUNT**
OXYCODONE HYDROCHLORIDE	260
HYDROCODONE BITARTRATE/AC	151
OMEPRAZOLE	107
AMPHETAMINE/DEXTROAMPHETA	96
SUBOXONE	93
Top Five Specialty Drugs by PA	
DRUG	**CLAIM COUNT**
MAVYRET	72
SYNAGIS	44
HUMIRA PEN	41
NEXPLANON	34
AIMOVIG	33

New FDA Drug Safety Communication on lamotrigine (Lamictal) – Drug Information Update
https://www.fda.gov/drugs/drug-safety-and-availability/studies-show-increased-risk-heart-rhythm-problems-seizure-and-mental-health-medicine-lamotrigine?utm_medium=email&utm_source=govdelivery

New studies show diabetes drug not proven to improve blood sugar control in pediatric patients
https://www.fda.gov/drugs/drug-safety-and-availability/new-studies-show-diabetes-drug-not-proven-improve-blood-sugar-control-pediatric-patients?utm_medium=email&utm_source=govdelivery

FDA Approves a Nasal Antihistamine for Nonprescription Use

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use?utm_medium=email&utm_source=govdelivery

FDA notifies Amgen of misbranding of its biological product, Neulasta, due to false or misleading promotional communications about the product's benefit
https://www.fda.gov/drugs/drug-safety-and-availability/fda-notifies-amgen-misbranding-its-biological-product-neulasta-due-false-or-misleading-promotional?utm_medium=email&utm_source=govdelivery

FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes?utm_medium=email&utm_source=govdelivery

Clozapine Risk Evaluation and Mitigation Strategy (REMS) requirements will change on November 15, 2021
https://www.fda.gov/drugs/drug-safety-and-availability/clozapine-risk-evaluation-and-mitigation-strategy-rems-requirements-will-change-november-15-2021?utm_medium=email&utm_source=govdelivery

Drug Utilization Review (DUR) Committee Meetings

Comments on the PDL or any PAs, either proposed or already in effect, may be made at these meetings or by e-mail, letter, or phone if more convenient.

Date: March 8,2022
Time: 5:30-8:30pm
Location: TBD

For DUR questions, you may contact:
Anne-Marie Toderico, PharmD, Pharmacy Director
Office of MaineCare Services
AnneMarie.Toderico@maine.gov

For PA/PDL questions, you may contact:
Michael Ouellette, R.Ph mouellette@changehealthcare.com
Jeffrey Barkin, MD jbarkin@changehealthcare.com

Pharmacy Help Desk Hours:

For emergencies the Pharmacy Help Desk 1-888-420-9711:

Monday- Friday 5pm-8pm
Saturday 8am- 8pm
Sunday 8am- 8pm

Please leave a message on the urgent voicemail and your call will be returned 15 minutes all non-urgent voicemails will be returned the next business day.